Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.
IPO Year: 2015
Exchange: NASDAQ
Website: gbt.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2022 | Outperform → Mkt Perform | William Blair | |
| 8/8/2022 | $40.00 → $72.00 | Hold → Buy | Canaccord Genuity |
| 3/28/2022 | $138.00 → $71.00 | Outperform | Wedbush |
| 2/28/2022 | $28.00 → $31.00 | Equal-Weight | Morgan Stanley |
| 2/24/2022 | $92.00 → $86.00 | Outperform | Oppenheimer |
| 12/21/2021 | $56.00 → $53.00 | Outperform | SVB Leerink |
| 12/14/2021 | $54.00 → $56.00 | Outperform | SVB Leerink |
| 12/7/2021 | Market Perform → Outperform | William Blair | |
| 11/5/2021 | $66.00 → $64.00 | Outperform | RBC Capital |
| 10/7/2021 | $68.00 | Buy | Jefferies |
William Blair downgraded Global Blood Therapeutics from Outperform to Mkt Perform
Canaccord Genuity upgraded Global Blood Therapeutics from Hold to Buy and set a new price target of $72.00 from $40.00 previously
Wedbush resumed coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $71.00 from $138.00 previously
Morgan Stanley reiterated coverage of Global Blood Therapeutics with a rating of Equal-Weight and set a new price target of $31.00 from $28.00 previously
Oppenheimer reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $86.00 from $92.00 previously
SVB Leerink reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $53.00 from $56.00 previously
SVB Leerink reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $56.00 from $54.00 previously
William Blair upgraded Global Blood Therapeutics from Market Perform to Outperform
RBC Capital reiterated coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $64.00 from $66.00 previously
Jefferies initiated coverage of Global Blood Therapeutics with a rating of Buy and set a new price target of $68.00
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors. Dr. Thompson, who brings decades of experience in clinical research, patient care, leadership and advocacy in hematology, will serve on the board’s research and development committee. “We’re thrilled to welcome Alexis to our board as we continue to pursue the transformation of care in sickle cell disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her deep expertise in blood
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of dire
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development. “As we enter a period of expected sustained growth for years to come, aligning our research and development teams under a single leader will make GBT even more efficient and productive in bringing innovative medicines to patients. We are absolutely thrilled to add Kim, a committed and accomplished global leader in sickle cell disease, to our senior management
Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA
Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease (SCD) treatment, research and education. The new legislation is sponsored by Congresswoman Barbara Lee of California, Congressman Danny Davis of Illinois, Senator Chris Van Hollen of Maryland and Senator Cory Booker of New Jersey. The bill would create a national network of SCD treatment centers in which healthcare providers and communit
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Month, is open to the public and will be live streamed on the SCD Therapeutics Conference website and the Facebook page of Sickle Cell Warriors, an SCD community organization. Admiral Rachel Levine, M.D., assistant secretary for health, U.S. Department of Health and Human Services (HHS), will provide remarks at the
NEW YORK, NY / ACCESSWIRE / August 27, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
NEW YORK, NY / ACCESSWIRE / August 20, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Lifshitz Law PLLC:Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request
NEW YORK, NY / ACCESSWIRE / August 13, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
NEW YORK, NY / ACCESSWIRE / August 10, 2022 /Global Blood Therapeutics, Inc. (NASDAQ:GBT)Lifshitz Law PLLC announces an investigation into GBT's sale to Pfizer Inc. for $68.50 per share.If you are a GBT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:AVLR)Lifshitz Law PLLC announces an investigation into AVLR's sale to Vista Equity Partners for $93.50 per share.If you are an AVLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Jos
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace
15-12G - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)
SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace
SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close. Management will host a conference call on Monday, August 8, 2022, at 4:30 p.m. ET to discuss second quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the e
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company's next-generation sickle hemo
Conference call and webcast will include data presented at EHA 2022 and business and R&D updates Company to also participate in the William Blair and Goldman Sachs investor conferences SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will host a conference call and webcast for the investment community on Friday, June 10, 2022, at 3:00 p.m. CEST (9:00 a.m. ET) to discuss data on its sickle cell programs presented at the European Hematology Association (EHA) Annual Congress and to provide business and R&D updates. To participate in the conference call, please dial (877) 407-3982 (domestic) or +1 (201)
Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 years and over Reinitiated GBT601 Phase 1 trial in sickle cell disease (SCD) patients to study 150 mg daily dose; on track to initiate Phase 2/3 trial by mid-year Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported financial results for the first quarter ended March 31, 2022, and recent business progress.
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss first quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the eve
Achieved Oxbryta® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted by pediatric label expansion in the U.S., marketing authorization for ages 12 and over in the EU, and advancement of R&D pipeline Strong balance sheet with cash and investments totaling $734.8 million at year end Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported financial results for the fourth quarter and year ended December 31, 2021, and recent business progress. "2021
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report fourth quarter and full year 2021 financial results on Wednesday, February 23, 2022, after U.S. financial markets close. Management will host a conference call on Wednesday, February 23, 2022, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and to provide a general business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast
GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies of SCD patients and healthy volunteers Study results provide proof of concept to support the continued development of GBT601 GBT to host investor conference call and webcast today at 12:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a Phase 1 study of GBT021601 (GBT601), the company's investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor, that demonstrat
Achieved Oxbryta® (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target action date of December 25, 2021 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported financial results for the third quarter ended September 30, 2021 and recent business progress. "Our third quarter results reflect progress with our ongoing initiatives to drive Oxbryta awareness, adoption and access, and like others in our industry, this was partially offset by the i